Development of novel nanoparticle based PLK1, EGFR, and PD-L1 targeted therapies for lung cancer Public Deposited
Non-small cell lung cancer (NSCLC) is the deadliest form of cancer and represents nearly a fourth of all cancer related deaths worldwide. Identifying molecular targets and developing effective therapeutic regimens to improve NSCLC treatments and patient quality of life is needed. Nanoparticles possess unique properties to enhance treatment efficacy and reduce toxic side effects of traditional therapies. In my dissertation, I exploited versatile mesoporous silica nanoparticles (MSNP) to improve radiation therapy and immunotherapy, which are two key treatments for NSCLC patients.